The angiogenic factor CYR61 in breast cancer: Molecular pathology and therapeutic perspectives

Endocrine-Related Cancer

Volumn 10, Issue 2, 2003, Pages 141-152

  Menendez J A ^a   Mehmi, I ^a   Griggs, D W ^b   Lupu, R ^a  

^a Evanston NW Hlthcare Res Inst   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; CYSTEINE; CYSTEINE RICH PROTEIN 61; ESTROGEN RECEPTOR; HEPARIN BINDING PROTEIN; INTEGRIN RECEPTOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; APOPTOSIS; AUTOCRINE EFFECT; BREAST CANCER; BREAST CARCINOGENESIS; CELL PROLIFERATION; CONFERENCE PAPER; DISEASE COURSE; GENE OVEREXPRESSION; HORMONE ACTION; HUMAN; MOLECULAR INTERACTION; NONHUMAN; PARACRINE SIGNALING; PHENOTYPE; PROTEIN FUNCTION; TUMOR CELL LINE;

ADENOCARCINOMA; ANGIOGENESIS INDUCING AGENTS; BREAST NEOPLASMS; CELL ADHESION; CELL DIVISION; CELL MOVEMENT; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMEDIATE-EARLY PROTEINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASM INVASIVENESS; NEOPLASMS, HORMONE-DEPENDENT;

EID: 0038274849     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0100141     Document Type: Conference Paper

References (77)

1. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM & McEwan RN 1987 A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Research 47 3239-3245.
2. Aoudjit F & Vuori K 2001 Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene 20 4995-5004.
3. Atlas, E, Mehmi I, Cardillo M, Tang CK & Lupu R 2003 Heregulin expression modulates tumor progression and angiogenesis of breast cancer cells in vivo. Molecular Cancer Research 1 165-175.
4. Babic AM, Kireeva ML, Kolesnikova TV & Lau LF 1998 Cyr61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. PNAS 95 6355-6360.
5. 3, promotes endothelial cell survival, and induces angiogenesis in vivo. Molecular and Cellular Biology 19 2958-2966.
6. WAF1 and p53 requires c-raf-1. Cancer Research 55 4623-4626.
7. Brigstock DR 1999 The connective tissue growth factor/cysteine rich 61/nephroblastoma overexpressed (CCN) family. Endocrinology Reviews 20 189-206.
8. Brigstock DR, Goldschmeding R, Katsube KI, Lam SC, Lau LF, Lyons K, Naus C, Perbal B, Riser B, Takigawa M & Yeger H 2003 Proposal for a unified CCN nomenclature. Molecular Pathology 56 127-128.
9. Brown P, Fuqua S & Allred C 2000 Pathogenesis of estrogen-positive and negative breast cancer. In Contemporary Endocrinology: Endocrine Oncology, pp 49-68. Ed SP Ethier. Totowa, NJ, USA: Humana Press Inc.
10. Cardillo, M, Tang C & Lupu R 1995 Heregulin induces a metastatic phenotype to breast cancer cells in vivo. Proceedings of American Association for Cancer Research 36 262.
11. Cavailles V, Augereau P, Garcia M & Rochefort H 1988 Estrogens and growth factors induce the mRNA of the 52K-pro-cathepsin-D secreted by breast cancer cells. Nucleic Acids Research 16 1903-1919.
12. Charles CH, Abler AS & Lau LF 1991 cDNA sequence of a growth factor-inducible immediate early gene and characterization of its encoded protein. Oncogene 8 23-28.
13. Chen N, Chen CC & Lau LF 2000 Adhesion of human skin fibroblasts to Cyr61 is mediated through integrin α6β1 and cell surface heparan sulfate proteoglycans. Journal of Biological Chemistry 275 24953-24961.
14. Chen N, Chen CC & Lau LF 2001 Cyr61, a product of a growth factor-inducible immediate early gene, is associated with the extracellular matrix and the cell surface. Journal of Biological Chemistry 176 10443-10452.
15. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA & Dalton WS 1999 Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 93 1658-1667.
16. Engleman VW, Nickols GA, Ross FP, Horton MA, Griggs DW, Settle SL, Ruminski PG & Teitelbaum SL 1997 A peptidomimetic antagonist of the α(v)β3 integrin inhibits bone absorbation in vitro and prevents osteoporosis in vivo. Journal of Clinical Investigation 99 2284-2292.
17. Frazier K, Williams S, Kothapalli D, Klapper H & Grotendorst GR 1996 Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor. Journal of Investigative Dermatology 107 404-411.
18. 3: a new prognostic indicator in breast cancer. Clinical Cancer Research 4 2625-2634.
19. Gehring M, Berthold F, Edler L, Schwab M & Amler LC 1995 The 1 p deletion is not a reliable marker for the prognosis of patients with neuroblastoma. Cancer Research 55 5366-5369.
20. Giannakakou P, Robey R, Fojo T & Blagosklonny MV 2001 Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity. Oncogene 20 3806-3813.
21. Gilmore AP, Metcalfe AD, Romer LH & Streuli CH 2000 Integrin-mediated survival signals regulate the apoptotic function of Bax through its conformation and subcellular localization. Cellular Biology 149 431-436.
22. Grzeszkiewicz TM, Kirschling DJ, Chen N & Lau LF 2001 CYR61 stimulates human skin fibroblast migration through integrin αvβ5 and enhances mitogenesis through integrin αvβ3, independent of its carboxyl-terminal domain. Journal of Biological Chemistry 276 21943-21950.
23. Hainsworth PJ, Raphael KL, Stillwell RG, Bennett RC & Garson OM 1992 Rearrangement of chromosome 1p in breast cancer correlates with poor prognostic features. British Journal of Cancer 66 131-135.
24. Harris LN, Yang L, Tang C, Yang D & Lupu R 1998 Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin β-2. Clinical Cancer Research 4 1005-1012.
25. Hijazi MM, Thompson EW, Tang C, Coopman P, Torri JA, Yang D, Mueller SC & Lupu R 2000 Heregulin regulates the actin cytoskeleton and promotes invasive properties in breast cancer cell lines. International Journal of Oncology 17 629-641.
26. Hu L, Hofmann J, Lu Y, Mills GB & Jaffe RB 2002 Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Research 62 1087-1092.
27. Jay P, Berge-Lefranc L, Marsollier C, Mejean S, Taviaux S & Berta P 1997 The human growth factor-inducible immediate early gene, Cyr61, maps to chromosome 1p. Oncogene 14 1753-1757.
28. Jedsadayanmata A, Chen CC, Kireeva ML, Lau LF & Lam SCT 1999 Activation-dependent adhesion of human platelets to connective tissue growth factor (CTGF) and CYR61 is mediated through integrin αIIβ33. Journal of Biological Chemistry 274 24321-24327.
29. Kerbel RS, Viloria-Petit A, Klement G & Rak J 2000 'Accidental' anti-angiogenic drugs: anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. European Journal of Cancer 36 1248-1257.
30. King WG, Mattaliano MD, Chan TO, Tsichlis PN & Brugge JS 1997 Phosphatidylinositol 3-kinase is required for integrin-stimulated AKT and Raf-1/mitogen-activated protein kinase pathway activation. Molecular and Cellular Biology 17 4406-4418.
31. Kireeva ML, Mo F-E, Yang GP & Lau LF 1996 Cyr61, a product of a growth factor-inducible immediate early gene, promotes cell proliferation, migration, and adhesion. Molecular and Cellular Biology 16 1326-1334.
32. Kireeva ML, Latinkic BV, Kolesnikova TV, Chen C-C, Yang G P, Abler AS & Lau LF 1997 Cyr61 and Fisp12 are both signaling cell adhesion molecules: comparison of activities, metabolism, and localization during development. Experimental Cell Research 233 63-77.
33. 3. Journal of Biological Chemistry 273 3090-3096.
34. Kolesnikova TV & Lau LF 1998 Human CYR61-mediated enhancement of bFGF-induced DNA synthesis in human umbilical vein endothelial cells. Oncogene 16 747-754.
35. Lau LF & Lam S C-T 1999 The CCN family of angiogenic regulators: the integrin connection. Experimental Cell Research 248 44-57.
36. Lau LF & Nathans D 1985 Identification of a set of genes expressed during G0/G1 transition of cultured mouse cells. EMBO Journal 4 3145-3151.
37. Lau LF & Nathans D 1987 Expression of a set of growth-related immediate early genes in BALB/c3T3 cells coordinate regulation with c-fos or c-myc. PNAS 84 1182-1186.
38. Lee JW & Juliano RL 2000 α5β1 integrin protects intestinal epithelial cells from apoptosis through a phosphatidylinositol 3-kinase and protein kinase-B dependent pathway. Molecular and Cellular Biology 11 1973-1987.
39. Leu SJ, Lam SC & Lau LF 2002 Pro-angiogenic activities of CYR61 (CCNI) mediated through integrins αvβ3 and α6β1 in human umbilical vein endothelial cells. Journal of Biological Chemistry 277 46248-46255.
40. Lissoni P, Fugamalli E, Malugani F, Ardizzoia A, Secondino S, Tancini G & Gardani GS 2000 Chemotherapy and angiogenesis in advanced cancer: vascular endothelial growth factor (VEGF) decline as predictor of disease control during Taxol therapy in metastatic breast cancer. International Journal of Biological Markers 15 308-312.
41. Lupu R, Cardillo M, Harris L, Hijazi M & Rosenberg K 1995 Interaction between erbB-receptors and heregulin in breast cancer tumor progression and drug resistance. Seminars in Cancer Biology 6 135-145.
42. Lupu R, Cardillo M, Cho C, Harris L, Hijazi M, Perez C, Rosenberg K, Yang D & Tang C 1996 The significance of heregulin in breast cancer tumor progression and drug resistance. Breast Cancer Research and Treatment 38 57-66.
43. MacGregor JI & Jordan VC 1998 Basic guide to the mechanisms of antiestrogen action. Pharmacology Reviews 50 151-196.
44. MacKeigan JO, Taxman DJ, Hunter D, Earp HS III, Graves LM & Ting JP 2002 Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of Taxol and mitogen-activated protein kinase inhibition. Clinical Cancer Research 8 2091-2099.
45. 3. European Journal of Cancer 38 (Suppl 7) 108.
46. 3. (In Press).
47. Meyer T, Marshall JF & Hart TR 1998 Expression of αv integrins and vitronectin receptor identity in breast cancer cells. British Journal of Cancer 77 530-536.
48. Miller KD, Sweeney CJ & Sledge GW Jr 2001 Redefining the target: chemotherapeutics as antiangiogenics. Journal of Clinical Oncology 19 1195-1206.
49. WAF1/CIP1/SD11 induced by cisplatin and paclitaxel. Cancer Research 60 5390-5394.
50. Nathans D, Lau LF, Christy B & Ryder K 1988 The genomic response to growth factors. Cold Spring Harbor Symposium on Quantitative Biology 53 893-900.
51. Nicholson RI & Gee JM 2000 Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer. British Journal of Cancer 82 501-513.
52. Nicholson RI, Gee JM, Francis AB, Manning DL, Wakeling AE & Katzenellenbogen BS 1995 Observations arising from the use of pure antioestrogens on oestrogen-responsive (MCF-7) and oestrogen growth-independent (K3) human breast cancer cells. Endocrine-Related Cancer 2 115-121.
53. O'Brien TP & Lau LF 1992 Expression of the growth factor-inducible immediate early gene correlates with chondrogenesis during mouse embryonic development. Cell Growth and Differentiation 3 645-654.
54. O'Brien TP, Yang GP, Sanders L & Lau LF 1990 Expression of Cyr61, a growth factor inducible immediate-early gene. Molecular and Cellular Biology 10 3569-3577.
55. Perbal B 2001 The CCN family of genes: a brief history. Molecular Pathology 54 103-104.
56. Perez EA 1998 Paclitaxel in breast cancer. Oncologist 3 373-389.
57. Pratt SE & Pollak MN 1993 Estrogen and antiestrogen modulation of MCF7 human breast cancer cell proliferation is associated with specific alterations in accumulation of insulin-like growth factor-binding proteins in conditioned media. Cancer Research 53 5193-5198.
58. Rivera-Gonzalez R, Petersen DN, Tkalcevic G, Thompson DD & Brown TA 1998 Estrogen-induced genes in the uterus of ovariectomized rats and their regulation by droloxifene and tamoxifen. Journal of Steroid Biochemistry and Molecular Biology 64 13-24.
59. Saceda M, Grunt TW, Colomer R, Lippman ME, Lupu R & Martin MB 1996 Regulation of estrogen receptor concentration and activity by an erbB/HER ligand in breast carcinoma cell lines. Endocrinology 137 4322-4330.
60. Sampath D, Winneker RC & Zhang Z 2001 Cyr61, a member of the CCN family, is required for MCF-7 cell proliferation: regulation by 17β-estradiol and overexpression in human breast cancer. Endocrinology 142 2540-2548.
61. Seidman AD, Hudis CA, Fennelly D, Raptis G, Baselga J & Norton L 1995 Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer. Seminars in Oncology 5 (Suppl 12) 108-116.
62. Shin E, Fujita S, Takami K, Kurahshi H, Kurita Y, Kobayshi T, Mori T, Nishisho I & Takai S 1993 Deletion mapping of chromosome 1p and 22q in pheochromocytoma. Japanese Journal of Cancer Research 84 402-408.
63. Simon D, Knowles BB & Weith A 1991 Abnormalties of chromosome 1p and loss of heterozygosity on 1p in primary hepatomas. Oncogene 6 765-770.
64. Sommer CL, Byers SW, Thompson EW, Torri JA & Gelmann EP 1994 Differentiation state and invasiveness of human breast cancer cell lines. Breast Cancer Research and Treatment 31 325-335.
65. Tang C, Grunt T, Cho C, Weibel C, Perez C & Lupu R 1996 Involvement of heregulin β-2 in the acquisition of the hormone-independent phenotype of breast cancer cells. Cancer Research 56 3350-3358.
66. Thompson EW, Paik S, Brunner N, Sommers CL, Zugmaier G, Clarke R, Shima TB, Torri J, Donahue S & Lippman ME 1992 Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. Journal of Cellular Physiology 150 534-544.
67. Tran J, Master Z, Lu JL, Rak J, Dumont D & Kerbel R 2002 A role for surviving in chemoresistance of endothelial cells mediated by VEGF. PNAS 99 4349-4354.
68. Tsai M-S, Hornby AE, Lakins J & Lupu R 2000 Expression and function of CYR61, an angiogenic factor, in breast cancer cell lines and tumor biopsies. Cancer Research 60 5603-5607.
69. Tsai M-S, Bogart DF, Castaneda JM, Li P & Lupu R 2002a Cyr61 promotes breast tumorigenesis and cancer progression. Oncogene 21 8178-8185.
70. Tsai M-S, Bogart DF, Li P, Mehmi I & Lupu R 2002b Expression and regulation of Cyr61 in human breast cancer cell lines. Oncogene 21 964-973.
71. Tsai M-S, Mehmi I, Bogart DF, Castaneda J & Lupu R 2002c Cyr61 induces breast tumorigenicity and promotes breast cancer progression through regulation of the MAPK and AKT signaling pathways. Proceedings of the AACR 43.
72. Weaver CA, Springer PA & Katzenellenbogen BS 1988 Regulation of pS2 gene expression by affinity labeling and reversibly binding estrogens and antiestrogens: comparison of effects on the native gene and on pS2-chloramphenicol acetyltransferase fusion genes transfected into MCF-7 human breast cancer cells. Molecular Endocrinology 2 936-945.
73. Wong M, Kireeva ML, Kolesnikova TV & Lau LF 1997 Cyr61, product of a growth factor-inducible immediate early gene, regulates chondrogenesis in mouse limb bud mesenchymal cells. Developmental Biology 192 492-508.
74. Xie D, Miller CW, O'Kelly J, Nakachi K, Sakashita A, Said JW, Gorbein J & Koeffler HP 2001a Breast cancer: Cyr61 is overexpressed, estrogen-inducible, and associated with more advanced disease. Journal of Biological Chemistry 276 14187-14194.
75. Xie D, Nakachi K, Wang H, Elashoff R & Koeffler P 2001b Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancer associated with more advanced features. Cancer Research 61 8917-8923.
76. Yang PG & Lau FL 1991 Cyr61, product of a growth factor-induced immediate early gene, is associated with the extracellular matrix and the cell surface. Cell Growth and Differentiation 2 351-357.
77. Zhang XS, Zhu XF, Gao JS, Qian CN, Kuang ZJ, Liu ZC & Zeng YX 2001 Multiple drug resistance phenotype of human endothelial cells induced by vascular endothelial growth factor 165. Acta Pharmacologica Singapura 22 731-735.